About Us
Dynamix Biotechnology Inc. - DBI is a rapidly emerging biotech company dedicated to the commercialization of a treatment for Sarcoidosis.
Currently focusing efforts on DB-602, an injectable peptide that in extensive studies conducted has shown a greater efficacy than current FDA approved treatments.
Technology developed by Dr Andrew Schally, a Noble Prize winning Endooncologist and Dr Mehdi MirSaeidi who is the Chief of Pulmonology division at the University of Florida (UF)
TEAM
Shahab Mahidashti
Saeid Rezvankhah, MSF MSEd
Saeid Rezvankhah, MSF MSEd
Chief Executive Officer
and Co-Founder
Saeid Rezvankhah, MSF MSEd
Saeid Rezvankhah, MSF MSEd
Saeid Rezvankhah, MSF MSEd
Chief Operating Officer
and Co-Founder
Stanley Kim, PhD. JD
Saeid Rezvankhah, MSF MSEd
Stanley Kim, PhD. JD
VP of Intellectual Property
David Campo
Saeid Rezvankhah, MSF MSEd
Stanley Kim, PhD. JD
Co-Founder,
Regulatory & Quality